MedTrace Logo

Efficacy of a Mindfulness-Based Intervention in Patients With Cardiovascular Implantable Electronic Device

NCT06021236 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-04-14

No results posted yet for this study

Summary

An implantable cardiac defibrillator (implantable cardioverter-defibrillator; ICD) can effectively improve heart rhythm problems and reduce sudden death, and is widely used in the treatment of high-risk patients with fatal arrhythmias or heart rhythm problems that cannot be controlled by drugs . In the whole case of arrhythmia, after receiving home-based cardiac fibrillator treatment, Patients often experience uncertainty, feel the changes in heart, feel the shock of being shocked by the electric shock, and worry about death, These psychological distress, which were characterized by anxiety and depression. for universal. About 25% of patients present with symptoms of anxiety at the time of hospitalization, and 50% suffer from depression which seriously affects quality of life. Therefore, the main purpose of this study to alleviate the occurrence of anxiety and depression, promote disease patients to regain life adaptation, develop accessible care strategies with midfulness-based intervention to help patients overcome psychological distress, reduce stress, anxiety and prevent depression.

Conditions

  • Mindfulness Training
  • Cardiac Resynchronization Therapy Devices
  • Resilience, Psychological
  • Anxiety
  • Depression
  • Perceived Stress

Interventions

BEHAVIORAL

mindfulness-based intervention

Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing

OTHER

CIED procedure routine care

CIED procedure home care guidance

Sponsors & Collaborators

  • National Taipei University of Nursing and Health Sciences

    collaborator OTHER

  • Chien Chih-Yin

    lead OTHER

Principal Investigators

  • CY Chien, PI · MKC/MMH

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06021236 on ClinicalTrials.gov